Top Markets
#1 TENDIES TENDIES +59.67%
#2 Threshold Network Threshold Network +58.79%
#3 Cash Cat Cash Cat +21.23%
#4 OSK OSK +15.93%
#5 Magma Finance Magma Finance +13.61%
#6 Falcon Finance Falcon Finance +12.83%
#7 Ape and Pepe Ape and Pepe +12.62%
#8 Kite Kite +11.86%
#9 Maple Finance Maple Finance +11.45%
#10 Asteroid Shiba Asteroid Shiba +9.44%
Coin of the day
TENDIES TENDIES
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Cellectis S.A. Cellectis S.A.

Cellectis S.A.

ALCLS
Rang in aandelen #17125
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and... Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Aandeelprijs
$3.56
Marktkapitalisatie
$257.37M
Verandering (1 dag)
5.26%
Verandering (1 jaar)
38.35%
Land
FR
Handel Cellectis S.A. (ALCLS)

Categorie

Healthcare
Dividendgeschiedenis van Cellectis S.A. (ALCLS)
Cellectis S.A. (aandelsymbool: ALCLS) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Cellectis S.A. (ALCLS) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH